Market capitalization | $50.27m |
Enterprise Value | $-1.85m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.02 |
P/B ratio (TTM) P/B ratio | 0.51 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-124.80m |
Free Cash Flow (TTM) Free Cash Flow | $-104.94m |
Cash position | $85.94m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
9 Analysts have issued a Vor Biopharma Inc forecast:
9 Analysts have issued a Vor Biopharma Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -4.82 -4.82 |
49%
49%
|
|
EBITDA | -120 -120 |
18%
18%
|
EBIT (Operating Income) EBIT | -125 -125 |
12%
12%
|
Net Profit | -118 -118 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Bob Ang |
Employees | 168 |
Founded | 2015 |
Website | www.vorbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.